Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.02, 5.08, 8.01, 9.01 · 8-K

Vivos Inc

RDGLOTCEQUITYCurrent

Unregistered Sales of Equity Securities · Shareholder Director Nominations · Other Events

Item 3.02 Unregistered Sales of Equity Securities Issuance of Common Stock Pursuant to Offering Statement On October 30, 2026, Vivos Inc. (the “ Company ”) completed the sale and issuance of 12,500,000 shares of common stock, par value $0.001 per share (“ Common Stock ”), pursuant to its Regulation A+ offering being conducted on a “best efforts” basis under Regulation A of Section 3(6) of the Secu…

Filed Nov 5, 2026Accepted Nov 5, 2026, 8:54 AM ESTCIK 1449349Accession 0001493152-26-050077
Share

Company context

Current securities

Historical securities (6)

Recent company filings

  1. 10-Q filingNov 12, 2026
  2. DEF 14A filingNov 9, 2026
  3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 8, 2026
  4. 8-K filingOct 5, 2026
  5. 10-Q filingAug 12, 2026

Disclosure sections

Items 3.02, 5.08, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02 Unregistered Sales of Equity Securities Issuance of Common Stock Pursuant to Offering Statement On October 30, 2026, Vivos Inc. (the “ Company ”) completed the sale and issuance of 12,500,000 shares of common stock, par value $0.001 per share (“ Common Stock ”), pursuant to its Regulation A+ offering being conducted on a “best efforts” basis under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “ Securities Act ”) (the “ Offering ”). The Offering is being conducted pursuant to the Company’s offering statement on Form 1-A, dated March 4, 2026 (“ Offering Statement ”), as filed with and qualified by the Securities and Exchange Commission (the “ SEC ”) on March 5, 2026. The Offering resulted in gross proceeds to the Company of $1,000,000. Proceeds from the sale of Common Stock in connection with the Offering will be used for general working capital purposes. Please see the Offering Statement for additional details regarding the Offering, including the terms of the Common Stock being offered. The issuance of the Common Stock was made in reliance upon an exemption from registration provided under Regulation A+ pursuant to Section 3(6) of the Securities Act. Issuance of Warrants On October 30, 2026, the Company completed the sale and issuance to certain accredited investors of warrants to purchase 25,000,000 shares of its Common Stock (the “ Warrants ”), in consideration of an aggregate of $25,000, which warrants expire, if not previously exercised, on December 31, 2030, and are exercisable for Common Stock at $.075 per share. The Warrants were issued pursuant to Regulation D under the Securities Act. Warrant Exchange On October 30, 2026, the Company completed the issuance of 8,000,000 shares of Common Stock (the “ Exchange Shares ”) in consideration for the cancellation of 8,000,000 warrants to purchase shares of Common Stock (the “ Warrant Exchange ”). The Exchange Shares were issued in reliance on Sections 3(a)(9) and 4(2) of the Securities Act. The foregoing descriptions of the Warrant and Warrant Exchange Agreement do not purport to be complete and are qualified in their entirety by the full text of the Form of Warrant and Form of Exchange Agreement filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K, and are incorporated by reference herein. Item 5.08. Shareholder Director Nominations. The Company will host its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) virtually on December 9, 2026. The Company’s Board of Directors has set a record date of November 2, 2026, entitling stockholders of record as of such date to notice of and to vote at the 2026 Annual Meeting. As provided in Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) (“ Rule 14a-8 ”), the Company is hereby providing the date by which shareholder proposals must be received by the Company to be included in the proxy statement for the Annual Meeting. The Company will provide additional details regarding the matters to be voted on and instructions for accessing the Annual Meeting in the Company’s proxy statement to be filed with the SEC prior to the Annual Meeting. To be considered for inclusion in proxy materials for the Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 and intended to be presented at the Annual Meeting must be received by the Company at 1030 N Center Parkway, Kennewick, WA 99336 no later than the close of business on November 9, 2026. Any proposal received after such date will be considered untimely. All Rule 14a-8 proposals must be in compliance with applicable laws and regulations in order to be considered for inclusion in the Company’s proxy materials for the Annual Meeting. The public announcement of an adjournment or postponement of the date of the Annual Meeting will not commence a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8. Further, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by November 9, 2026.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events See Item 3.02 above.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.